These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39084554)

  • 1. Real-World 1-Year Outcomes of Treatment-Intensive Neovascular Age-Related Macular Degeneration Switched to Faricimab.
    Sim SY; Chalkiadaki E; Koutsocheras G; Nicholson L; Sivaprasad S; Patel PJ; Selvam S; Pal B; Keane PA; Bhatia B; Hamilton R;
    Ophthalmol Retina; 2024 Jul; ():. PubMed ID: 39084554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Treatment-Resistant Neovascular Age-Related Macular Degeneration Switched from Aflibercept to Faricimab.
    Raimondi R; Falfeli T; Bogdanova-Bennet A; Varma D; Habib M; Kotagiri A; Steel DH; Grinton M
    Ophthalmol Retina; 2024 Jun; 8(6):537-544. PubMed ID: 38040055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
    Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
    Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration.
    Cheng AM; Joshi S; Banoub RG; Saddemi J; Chalam KV
    Cureus; 2023 Jun; 15(6):e40100. PubMed ID: 37425528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population.
    Ibrahim FNI; Teo KYC; Tan TE; Chan HH; Chandrasekaran PR; Lee SY; Tan ACS; Mathur R; Chan CM; Sim SS; Tan GSW; Yeo IYS; Cheung CMG
    Front Ophthalmol (Lausanne); 2023; 3():1346322. PubMed ID: 38982998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.
    Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M
    Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration.
    Pandit SA; Momenaei B; Wakabayashi T; Mansour HA; Vemula S; Durrani AF; Pashaee B; Kazan AS; Ho AC; Klufas M; Regillo C; Yonekawa Y; Hsu J; Kuriyan A; Chiang A
    Ophthalmol Retina; 2024 Apr; 8(4):360-366. PubMed ID: 37913992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
    Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration.
    Coney JM; Zubricky R; Sinha SB; Sonbolian N; Zhou L; Hull TP; Lewis SA; Miller DG; Novak MA; Pendergast SD; Pham H; Platt SM; Rao LJ; Schartman JP; Singerman LJ; Donkor R; Fink M; McCoy J; Karcher H
    Int J Retina Vitreous; 2023 Feb; 9(1):8. PubMed ID: 36726178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration.
    Leung EH; Oh DJ; Alderson SE; Bracy J; McLeod M; Perez LI; Bottini A; Chin Yee D; Mukkamala K
    Clin Ophthalmol; 2023; 17():1287-1293. PubMed ID: 37181079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration.
    Hikichi T
    Jpn J Ophthalmol; 2023 Nov; 67(6):652-656. PubMed ID: 37861941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Weekly Efficacy Analysis of Faricimab in Patients with Age-Related Macular Degeneration.
    Muth DR; Fasler KF; Kvanta A; Rejdak M; Blaser F; Zweifel SA
    Bioengineering (Basel); 2024 May; 11(5):. PubMed ID: 38790345
    [No Abstract]   [Full Text] [Related]  

  • 13. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
    Takahashi H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Kawashima H; Yanagi Y
    Sci Rep; 2024 Apr; 14(1):9087. PubMed ID: 38643252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
    Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
    Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
    Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration.
    Kishi M; Miki A; Kamimura A; Okuda M; Matsumiya W; Imai H; Kusuhara S; Nakamura M
    J Clin Med; 2023 Aug; 12(15):. PubMed ID: 37568546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice.
    Guymer R; Bailey C; Chaikitmongkol V; Chakravarthy U; Chaudhary V; Finger RP; Gallego-Pinazo R; Chuan AKH; Ishida S; Lövestam-Adrian M; Parravano M; Luna Pinto JD; Schmitz-Valckenberg S; Sheth V; Souied EH; Chi GC; Gilberg F; Glittenberg C; Scheidl S; Bengus M
    Ophthalmol Sci; 2024; 4(3):100442. PubMed ID: 38304609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
    Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
    Ophthalmology; 2024 Aug; 131(8):914-926. PubMed ID: 38382813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
    Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
    Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
    Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
    Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.